⌘K
Loading ticker…
As of 2026-08-24, Artelo Biosciences, Inc. Common Stock (ARTL) has a 3-month relative strength percentile of 9 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 26. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 9.8%, relative volume 0.20×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
ARTL is in a stage 4 downtrend, week 12. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -29.6% / -80.5%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
ARTL appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $12K notional.
Held by 1 ETFs · $12K across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $12K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARTL Jan avg: 16.20% median: 12.31% win: 75% σ: 17.02% n: 4 2022-04-12 → 2026-07-31 | ARTL Feb avg: -10.57% median: -10.93% win: 25% σ: 16.50% n: 4 2022-04-12 → 2026-07-31 | ARTL Mar avg: 17.79% median: -11.06% win: 25% σ: 63.40% n: 4 2022-04-12 → 2026-07-31 | ARTL Apr avg: -18.24% median: -12.44% win: 20% σ: 24.91% n: 5 2022-04-12 → 2026-07-31 | ARTL May avg: -11.37% median: -0.40% win: 40% σ: 28.54% n: 5 2022-04-12 → 2026-07-31 | ARTL Jun avg: 19.11% median: -2.19% win: 40% σ: 52.36% n: 5 2022-04-12 → 2026-07-31 | ARTL Jul avg: -7.36% median: -3.02% win: 40% σ: 14.85% n: 5 2022-04-12 → 2026-07-31 | ARTL Aug avg: -12.95% median: -12.85% win: 0% σ: 12.00% n: 4 2022-04-12 → 2026-07-31 (current) | ARTL Sep avg: -24.44% median: -18.49% win: 0% σ: 18.12% n: 4 2022-04-12 → 2026-07-31 | ARTL Oct avg: -15.42% median: -16.11% win: 25% σ: 14.51% n: 4 2022-04-12 → 2026-07-31 | ARTL Nov avg: -13.86% median: -11.64% win: 25% σ: 22.95% n: 4 2022-04-12 → 2026-07-31 | ARTL Dec avg: -2.50% median: 1.20% win: 75% σ: 19.80% n: 4 2022-04-12 → 2026-07-31 |